Merck Licenses a Weight-Loss Pill. It’s Bad News for Obesity Biotechs.
The low-risk approach by the drug giant is a sign of the extent of Eli Lilly and Novo Nordisk’s dominance in the weight-loss ...
Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal
Merck will pay Hansoh $112 million upfront for rights to the drug, with the potential for an additional $1.9 billion in ...
Merck Snags Chinese Obesity Drug in Nearly $2 Billion Deal
Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion.
Merck, Hansoh Pharma in Obesity Pill License Potentially Worth More Than $2 Billion
Merck & Co. is licensing a potential oral obesity drug from Hansoh Pharma in a deal potentially worth more than $2 billion to the Chinese biopharmaceutical company.
Merck Joins With Chinese Distributor On Weight Loss Pill
( MENAFN - Baystreet) Merck (NYSE:MRK) on Wednesday said it has snagged the rights to an experimental weight loss pill from ...
Yahoo Finance6d
Merck reaches weight-loss drug deal worth up to $2 billion with China-based Hansoh
Merck announced a weight loss drug deal Wednesday with China-based Hansoh worth up to $2 billion for the pill code-named HS-10535. It includes an upfront $112 million licensing rights payment for ...
NBC Chicago6d
Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal
Merck on Wednesday said it has snagged the rights to an experimental weight loss pill from Chinese drugmaker ... are racing to develop more convenient obesity pills that can compete with ...